Neil Woodford’s First Buys For His New Fund

Disclosures by RM2 International SA (LON:RM2), ReNeuron Group Plc (LON:RENE), e-Therapeutics plc (LON:ETX); speculation on AstraZeneca plc (LON:AZN) and BAE Systems plc (LON: BA).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaThe initial offer period for Neil Woodford’s new CF Woodford Equity Income Fund closed at noon last Thursday (19 June).

The renowned fund manager told us during the morning:

“I can’t pre-announce my exact investment intentions but I do have a clear idea of what the starting portfolio … will look like. … I can start to build the portfolio this afternoon. I intend to proceed in a careful and considered manner, with a strong, disciplined focus on valuation — I won’t buy any share for the portfolio unless I view its valuation as attractive”.

Mitchell Fraser-Jones, Woodford’s Head of Investment Communications, sounded excited a few hours later, saying of his boss: “He’s rather busy this afternoon!”

RM2 International

One of Woodford’s Thursday afternoon buys was revealed on Friday when AIM-listed pallets company RM2 International (LSE: RM2) disclosed that Woodford Investment Management had acquired 24,000,000 shares (7.5% of the company).

RM2’s non-executive directors are far more glamorous than its business, because they include ex-Diageo chief executive Paul Walsh and former Marks & Spencer boss Sir Stuart Rose. Not bad for a company whose current share price of 52p gives a market capitalisation of a mere £167m.

ReNeuron Group and e-Therapeutics

Drug-discovery firm e-Therapeutics (LSE: ETX) and stem-cell business ReNeuron (LSE: RENE), both AIM companies, also disclosed that Woodford had bought shares on Thursday afternoon.

Woodford Investment Management now owns 17.7% of e-Therapeutics, which has a market capitalisation of £73m at a current share price of 27.5p, and 14.9% of ReNeuron, which has a market capitalisation of £54m at a current share price of 3p.

The number of shares Woodford bought in each company was matched by an identical sale on the same day by his former employer Invesco Perpetual.

AstraZeneca and BAE Systems

Invesco Perpetual also made hefty sales of shares in AstraZeneca (LSE: AZN) and BAE Systems (LSE: BA) last week. Now, because these are companies with much bigger market capitalisations, Woodford — if he is currently buying stakes in them — may not reach a level that is disclosable to the market. It would depend on what weighting he gave them in his fund and how big the fund is. Woodford tells us: “We don’t believe it would be sensible to announce the total amount raised for the fund immediately for reasons of market sensitivity …”

However, Woodford is on record as saying that last month’s £50 a share offer by Pfizer for AstraZeneca was “very distant” from being a full valuation; Astra’s shares now trade at under £44. So, I reckon the master investor would be happy to buy.

BAE Systems is another long-time Woodford favourite, and the shares are currently trading at an undemanding 11 times forecast earnings with a well-above-market-average dividend yield of 4.8%. Again, this looks to me like a company Woodford will be interested in.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester does not own any shares mentioned in this article.

More on Investing Articles

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »